Login to Your Account



Avastin On File; Some Estimates Predict Quick Drug Availability

By Kim Coghill


Tuesday, September 30, 2003
Following Monday's announcement that Genentech Inc.'s Avastin biologics license application now is on file with the FDA, it's rumored that the anti-angiogenesis cancer drug proposed as a first-line therapy for metastatic colorectal cancer could enter the U.S. market within about six months. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription